Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Summary

Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calorie diet and increased physical activity. All participants will be randomized to at least 76 weeks of treatment to evaluate the effects on long term body weight changes, tolerability, and safety.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Obesity
• Overweight
• Chronic Weight Management

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

18 to 79 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Last updated on ClinicalTrials.gov

August 10, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites